Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Other Accumulated Expenses: 2018-2025

Historic Other Accumulated Expenses for Tg Therapeutics (TGTX) over the last 7 years, with Sep 2025 value amounting to $2.0 million.

  • Tg Therapeutics' Other Accumulated Expenses fell 39.57% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 39.57%. This contributed to the annual value of $4.6 million for FY2024, which is 212.85% up from last year.
  • Per Tg Therapeutics' latest filing, its Other Accumulated Expenses stood at $2.0 million for Q3 2025, which was down 11.66% from $2.3 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Other Accumulated Expenses high stood at $14.5 million for Q1 2021, and its period low was $807,000 during Q3 2022.
  • Over the past 3 years, Tg Therapeutics' median Other Accumulated Expenses value was $2.3 million (recorded in 2025), while the average stood at $2.6 million.
  • Per our database at Business Quant, Tg Therapeutics' Other Accumulated Expenses tumbled by 93.61% in 2022 and then surged by 232.84% in 2024.
  • Over the past 5 years, Tg Therapeutics' Other Accumulated Expenses (Quarterly) stood at $1.5 million in 2021, then declined by 22.69% to $1.2 million in 2022, then climbed by 26.52% to $1.5 million in 2023, then spiked by 212.85% to $4.6 million in 2024, then crashed by 39.57% to $2.0 million in 2025.
  • Its Other Accumulated Expenses was $2.0 million in Q3 2025, compared to $2.3 million in Q2 2025 and $2.9 million in Q1 2025.